Clinical Research Directory
Browse clinical research sites, groups, and studies.
Safety of Elacestrant in ER+/HER2- and ESR1 Mutations MBC
Sponsor: SciClone Pharmaceuticals
Summary
This study is a prospective non-interventional real-world study enrolling patients with advanced breast cancer who are ER+/HER2- and have ESR1- gene mutations, collecting information on patients' complaints, physical examination, laboratory tests, imaging tests and adverse events to observe the safety of elacestrant treatment.
Official title: Safety of Elacestrant in the Treatment of Advanced Breast Cancer Patients With ER+/HER2- and ESR1-mutations Who Have Progressed on at Least One Line of Endocrine Therapy: a Prospective, Non-interventional Real-world Study
Key Details
Gender
FEMALE
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
350
Start Date
2024-07-13
Completion Date
2026-08-01
Last Updated
2024-08-09
Healthy Volunteers
No
Interventions
ELacestrant
345 mg/day once daily oral dosing
Locations (1)
Hainan Hospital of Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine (Boao Research Hospital, Hainan)
Qionghai, Hainan, China